2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4573 Real-world molecular testing patterns and mutation prevalence in acute myeloid leukemia

Vanessa E Kennedy, MD, Weilong Li2, Anne Angiolillo, MD3, Jerline Hsin, PharmD4, Eros Papademetriou5, Anirban Ghosh6, Tarun Bhagnani, MS, BPharm7
1 Stanford University, Palo Alto, California, United States
2 Servier Pharmaceuticals, Boston, Massachusetts, United States
3 Servier Pharmaceuticals, Boston, Massachusetts, United States
4 Servier Pharmaceuticals, Boston, Massachusetts, United States
5 Inizio Ignite Putnam, New York, New York, United States
6 Inizio Ignite Putnam, Gurgaon, India
7 Servier Pharmaceuticals, Boston, Massachusetts, United States

Background:
Molecular biomarkers are crucial for guiding risk stratification and treatment selection in patients with acute myeloid leukemia (AML). An individual patient’s molecular profile can inform frontline therapy decisions, the role of allogeneic transplant, and the incorporation of a growing number of targeted therapies. Consequently, upfront molecular testing is now recommended for all patients by national and international guidelines. However, real-world (RW) evidence on molecular testing practices in patients with AML remains limited. This study characterized molecular testing patterns and mutation prevalence among patients with AML in routine RW clinical practice.

 

Methods:

Nationwide administrative claims from the Komodo Research Dataset linked with NeoGenomics molecular testing data were used to identify adult patients (≥18 years old) with confirmed AML diagnosed between January 1, 2018 and April 30, 2026 and ≥180 days of continuous insurance coverage before AML diagnosis. Overall molecular testing rates, including both cytogenetics/FISH and broader molecular assays, and specific testing rates for select targetable molecular biomarkers (IDH1, IDH2, NPM1, KMT2A rearrangement [KMT2Ar], and FLT3) were assessed. Testing rates were categorized as ‘at diagnosis’ (defined as ± 30 days from first date of AML diagnosis) and ‘any time’ (from 30 days pre-diagnosis until end of follow-up). Mutational prevalence and co-mutation patterns were determined from the subset of patients with available linked NeoGenomics testing results.

 

Results:
In total, 36,350 patients with AML were identified in the Komodo database, of whom 73.9% had molecular testing at any time, 56.0% received testing at diagnosis, and 17.9% received testing >30 days after diagnosis. Over time, testing rates showed a modest increase from 66.4% in 2018 to 77.1% in 2025.

 

Molecular testing rates were variable across patient subgroups. Testing was less common in younger patients (≤34 years old), at 68.8%, than in older patients (≥65 years old), at 74.2%. Patients with increased comorbidity were less likely to receive testing, with testing rates of 65.7% in patients with Charlson comorbidity index (CCI) ≥4 compared to 78.5% in patients with CCI of 0. Compared to the overall cohort, testing rates were notably lower in patients with specific comorbidities, including metastatic cancer (63.4%), congestive heart failure (61.8%), psychoses (59.8%), paralysis (44.1%), and other neurological diseases (57.7%). Insurance status also impacted testing rates, with testing more common in patients with commercial insurance (76.2%) compared to Medicare (73.2%), Medicaid (71.6%), or missing/unknown insurance status (70.7%).

The testing rate for any potentially targetable biomarker (IDH1, IDH2, NPM1, KMT2Ar, and FLT3) was 51.4%. Notably, among the 5462 patients who underwent testing and had testing results available from NeoGenomics, 33.7% were found to have at least one targetable mutation, with 10.4% exhibiting two or more such mutations. The observed prevalence rates for specific mutations were: FLT3, 20.3%; NPM1, 17.7%; IDH2, 10.9%; IDH1, 10.1%; and KMT2Ar, 3.9%. Key co-mutation patterns were: FLT3:NPM1, 6.7%; IDH1:NPM1, 1.7%; IDH2:NPM1, 1.7%; and FLT3:IDH1, 1.3%.

 

Conclusions:
Despite a growing evidence base for molecular testing in AML, significant gaps exist in RW testing utilization. Over one-fourth of AML patients do not receive testing, and this is impacted by age, comorbidity, and insurance status. When testing is performed, however, over one-third of patients are found to harbor at least one potentially targetable mutation, with 10.4% having two or more, thus presenting opportunities for therapies such as IDH1 and FLT3 inhibitors in the frontline setting. These findings underscore critical inconsistencies in the timely use of genomic testing in routine clinical practice, emphasizing the need to optimize personalized treatment strategies for all patients with AML.

Vanessa E Kennedy, MD: BMS - Honoraria; Blueprint - Honoraria; Syndax - Honoraria; Rigel - Honoraria; Eurofins-Viracor - Research Funding; Menarini-Stemline - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony); Daiichi-Sankyo - Consultancy (Includes expert testimony); Arog - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony)